Home Applications 213246 Application 213246
Type NDA
Sponsor LOXO ONCOLOGY INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 RETEVMO SELPERCATINIB CAPSULE;ORAL 40MG Yes No 002 RETEVMO SELPERCATINIB CAPSULE;ORAL 80MG Yes No
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N213246-001 RETEVMO SELPERCATINIB 40MG CAPSULE / ORAL RLD 2020-05-08 N213246-002 RETEVMO SELPERCATINIB 80MG CAPSULE / ORAL RLD, RS 2020-05-08
Orange Book patents# Current patent rows page 1 of 1 · 54 matching rows.
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 44 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 3 · 82 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 c2088c7a36db…2026-10-15 13:18:30 2026-09 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 c2088c7a36db…2026-09-14 22:38:34 2026-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 84e616aacf4f…2026-09-14 22:38:34 2026-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 84e616aacf4f…2026-08-18 06:07:40 2026-07 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N213246-001 RETEVMO 40MG CAPSULE / ORAL RLD 2020-05-08 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N213246-002 RETEVMO 80MG CAPSULE / ORAL RLD, RS 2020-05-08 5d02ea3f76ae…
Observed Orange Book patent history# Patent history page 1 of 53 · 2,110 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N213246-001 10112942 2037-10-10 Drug substance, Drug product 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124 2037-10-10 U-3450 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124 2037-10-10 U-3949 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124 2037-10-10 U-3950 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124 2037-10-10 U-3951 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851 2037-10-10 U-3450 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851 2037-10-10 U-3949 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851 2037-10-10 U-3950 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851 2037-10-10 U-3951 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10112942*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10137124*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10172851*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124 2038-10-10 U-3450 Drug substance 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124 2038-10-10 U-3949 Drug substance 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124 2038-10-10 U-3950 Drug substance 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124 2038-10-10 U-3951 Drug substance 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489 2038-10-10 U-3450 Drug product 2020-10-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489 2038-10-10 U-3949 Drug product 2020-10-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489 2038-10-10 U-3951 Drug product 2020-10-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489 2038-10-10 U-3950 Drug product 2020-10-26 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250 2038-10-10 U-3949 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250 2038-10-10 U-3951 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250 2038-10-10 U-3950 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250 2038-10-10 U-3450 2024-12-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10584124*PED 2039-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 10786489*PED 2039-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-001 12138250*PED 2039-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10112942 2037-10-10 Drug substance, Drug product 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124 2037-10-10 U-3450 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124 2037-10-10 U-3949 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124 2037-10-10 U-3951 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124 2037-10-10 U-3950 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851 2037-10-10 U-3951 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851 2037-10-10 U-3949 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851 2037-10-10 U-3950 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851 2037-10-10 U-3450 2020-06-05 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10112942*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10137124*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10172851*PED 2038-04-10 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N213246-002 10584124 2038-10-10 U-3450 Drug substance 2020-06-05 d4dbc9d85df4…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 19 · 752 observed states.
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 8 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0002-2980 RETEVMO selpercatinib Eli Lilly and Company NDA Current 0002-2980 RETEVMO selpercatinib Eli Lilly and Company NDA Current 0002-2980 RETEVMO selpercatinib Eli Lilly and Company NDA Current 0002-2980 RETEVMO selpercatinib Eli Lilly and Company NDA Current 0002-3977 RETEVMO selpercatinib Eli Lilly and Company NDA Current 0002-3977 RETEVMO selpercatinib Eli Lilly and Company NDA Current 0002-3977 RETEVMO selpercatinib Eli Lilly and Company NDA Current 0002-3977 RETEVMO selpercatinib Eli Lilly and Company NDA Current